Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method of analyzing hemoglobins

Inactive Publication Date: 2013-05-23
SEKISUI MEDICAL CO LTD
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention introduces a new method for analyzing hemoglobins. This method allows for quick and precise separation and analysis of hemoglobins using liquid chromatography. Previous techniques were limited in their ability to separate certain hemoglobins. The present invention allows for accurate and efficient analysis of hemoglobins in a short time.

Problems solved by technology

Consequently, the analysis may provide poor separation accuracy (e.g. detection of broad elution peaks or elution peaks in a bimodal distribution).
Especially, the number of cases requiring separation and detection of hemoglobin S is large because hemoglobin S is the most common abnormal hemoglobin and causes sickle cell disease which results in severe anemia.
If hemoglobins are eluted in broad elution peaks or elution peaks in a bimodal distribution, separation of the abnormal hemoglobins from normal hemoglobins is difficult and this difficulty may cause a negative impact on obtained measurements.
Furthermore, deteriorated blood samples tend to give broad elution peaks or elution peaks in a bimodal distribution compared to fresh blood samples.
This is because the amount of methemoglobin is increased due to deterioration.
Therefore, in the case of analysis of a preserved sample (e.g. re-examination), there is a possibility of a negative impact on obtained measurements.
However, no matter which technique is used among the techniques of Patent Literatures 1 to 3, HPLC measurement of a blood sample containing hemoglobins in various forms including oxyhemoglobin, deoxyhemoglobin, and methemoglobin possibly results in broad elution peaks or elution peaks in a bimodal distribution.
Such a degasser may cause fluctuations in elution times of hemoglobins and have a negative impact on separation of hemoglobins because its gas removing performance is not stable for a while immediately after start-up.
Especially, immediately after start-up or when the temperature of an eluent is unstable, the HPLC instruments are likely to cause fluctuations in elution times of hemoglobins and deterioration of quantification accuracy.
This extends the time before a first report of analysis for diabetes diagnosis using hemoglobin A1c as a marker although such analysis requires a rapid result.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of analyzing hemoglobins
  • Method of analyzing hemoglobins
  • Method of analyzing hemoglobins

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0075]A sample was prepared by diluting a hemoglobin S-containing blood sample 100-fold with a sample pre-treatment solution (phosphate buffer (pH 7.0) containing 0.1% by weight Triton X-100).

[0076]The used separation column was a column containing cation-exchange resin filler particles having sulfonic acid groups on the surfaces.

[0077]The used HPLC instrument was provided with an autosampler SIL-20AC (Shimadzu Corp.), a delivery pump LC-20AD (Shimadzu Corp.), a degasser DGU-20A5 (Shimadzu Corp.), a column oven CTO-20AC (Shimadzu Corp.), and a detector SPD-M20A (Shimadzu Corp.). The instrument was run under the following conditions:

[0078]eluent flow rate: 1.7 mL / min;

[0079]detection wavelength: 415 nm; and

[0080]amount of introduced sample: 10 μL.

[0081]Each portion of the sample was eluted and measured using the following eluents for the respective periods of time:

[0082]until 0.5 minutes after the start: eluent 1 (40 mmol / L phosphate buffer (pH 5.4) containing 60 mmol / L sodium perchlo...

example 2

[0090]A sample was prepared by dissolving glycohemoglobin control level II (Sysmex Corp.) in water for injection (200 μL), and further diluting the solution 100-fold with a sample pre-treatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1% by weight Triton X-100).

[0091]Another sample was prepared by diluting a hemoglobin S-containing blood sample 100-fold with the sample pre-treatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1% by weight Triton X-100).

[0092]The same separation column as that of Example 1 was used.

[0093]The same HPLC instrument as that of Example 1 was run under the following conditions:

[0094]flow rate: 1.7 mL / min;

[0095]detection wavelength: 415 nm; and

[0096]amount of introduced sample: 10 μL.

[0097]Each sample was eluted and measured by linear gradient of two eluents:

[0098]first eluent: eluent 6 (20 mmol / L phosphate buffer (pH 5.4) containing 30 mmol / L sodium perchlorate, 1 mmol / L sodium nitrite, and 1 mmol / L sodium azide); and

[0099]...

example 3

[0101]A sample was prepared by dissolving glycohemoglobin control level II (Sysmex Corp.) in water for injection (200 μL), and further diluting the solution 100-fold with a sample pre-treatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1% by weight Triton X-100, 1 mmol / L sodium nitrite, and 1 mmol / L sodium azide).

[0102]Another sample was prepared by diluting a hemoglobin S-containing blood sample 100-fold with the sample pre-treatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1% by weight Triton X-100, 1 mmol / L sodium nitrite, and 1 mmol / L sodium azide).

[0103]The samples were measured in the same manner as in Example 2, except that eluent 3 (40 mmol / L phosphate buffer (pH 8.0) containing 0.8% by weight Triton X-100, 300 mmol / L sodium perchlorate, and 1 mmol / L sodium azide) used in Example 1 was used as the second eluent. FIG. 4 are the resulting chromatograms.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An object of the present invention is to provide a method for analyzing hemoglobins which can accurately separate hemoglobins in a short time by liquid chromatography.The present invention provides a method for analyzing hemoglobins by liquid chromatography which includes pre-treating a sample with an oxidant and a binder for trivalent heme iron.

Description

TECHNICAL FIELD[0001]The present invention relates to a method for analyzing hemoglobins by separating hemoglobins by liquid chromatography.BACKGROUND ART[0002]High-performance liquid chromatography (HPLC) analysis of hemoglobins is a widely used technique. Specifically, this technique is used, for example, to quantify a glycohemoglobin known as hemoglobin A1c or to analyze abnormal hemoglobins for diagnosis of diabetes. For example, a method utilizing liquid chromatography has been known which separates hemoglobin components in a diluted hemolyzed blood sample by a cation-exchange method based on the difference in positive charge among the hemoglobin components. A recent increase in patients with diabetes has also increased the number of cases requiring measurement of hemoglobin A1c. This tendency has created a demand for more accurate, less time-consuming measurement by HPLC.[0003]Hemoglobins are present in the body in the forms of oxyhemoglobin that contains bound oxygen, deoxyhe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/72
CPCG01N30/06G01N2030/8831G01N2030/067G01N33/721G01N2440/00G01N30/34G01N30/96G01N2030/8822B01D15/362
Inventor TAIRA, HIROAKIOKA, TAKAYUKI
Owner SEKISUI MEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com